+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD355 mouse mAb (green) and negative control (red).    

  
  

CD355 antibody targets the CD355 antigen, also known as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), a cell-surface protein belonging to the TIM family. Initially identified in 2002. TIM-3 is expressed on immune cells, including activated T cells, regulatory T cells (Tregs), natural killer (NK) cells, and dendritic cells. It functions as an immune checkpoint regulator, modulating both adaptive and innate immune responses. TIM-3 interacts with ligands such as galectin-9. phosphatidylserine, and high-mobility group protein B1 (HMGB1), playing dual roles in immune activation and tolerance.

In pathological contexts, CD355/TIM-3 is implicated in immune exhaustion, particularly in chronic infections and cancers, where its overexpression on T cells correlates with suppressed anti-tumor immunity. Consequently, TIM-3 has emerged as a therapeutic target, with blocking antibodies explored in preclinical and clinical studies to rejuvenate immune responses. Anti-CD355 antibodies are also critical tools in research, enabling the detection of TIM-3 expression in flow cytometry, immunohistochemistry, and functional studies to dissect its role in autoimmune diseases, infectious diseases, and cancer immunotherapy.

The development of CD355 antibodies has advanced understanding of immune regulation, highlighting TIM-3 as a potential biomarker for disease progression and a candidate for combination therapies with other checkpoint inhibitors (e.g., anti-PD-1). However, its pleiotropic effects across cell types necessitate careful evaluation to balance therapeutic efficacy and immune-related adverse events.